secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2026-04-17T23:59:59+00:00
Accession:  0001214659-26-004806
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro annual meeting: all proposals pass, including reverse stock split up to 1:10
--------------------------------------------------------------------------------

- All seven director nominees elected, including William B. Horne, Milton C. Ault III, Stephan Jackman, Henry C. Nisser, Mark Gustafson, Lynne F. McGrath, Jeffrey Oram.
- Shareholders approved reverse stock split (Proposal 6): ratio 1:2 to 1:10, board discretion, before April 16, 2027. Vote: 1,150,722 for, 445,185 against.
- Ratification of Haskell & White LLP as independent auditor (Proposal 2): 1,454,276 for, 114,748 against, no broker non-votes.
- Advisory vote on executive compensation (Proposal 3) passed: 276,241 for, 124,274 against, with 1,185,412 broker non-votes.
- 2025 Stock Incentive Plan (Proposal 4) and equity issuance approval (Proposal 5) also passed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465926004806/0001214659-26-004806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465926004806/p4172668k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-26-004806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer